



Institutional Biosafety Committee Minutes

Date: Wednesday, August 19, 2026

Time: 9:30 AM

Location: Zoom Meeting

MEMBERS IN ATTENDANCE

Carroll, Ann M.
Finkernagel, Scott W.
Geri, Jacob Benjamin
Kaminsky, Stephen M.
Lieggi, Christine
McGuinn, Catherine
Ndhlovu, Lishomwa (Lish)
Otero, Miguel
Schnappinger, Dirk

MEMBERS ABSENT

Busch, Robert H
Repik, Gabrielle
Wagner, John A.

STAFF

Gonzalez Russi, Sabrina
Lejb, Katarzyna

Meeting Minutes for Approval:

- July 15, 2026

No issues were raised and the committee approved the minutes from July 15, 2026.

Safety Officer Report

New Business

Conflicts of Interest Disclosure:

No member of the IBC may participate in the review of any project in which the IBC member is an investigator, has a financial conflict of interest, or has any other interest which has an adverse impact on the IBC member's ability to exercise independent judgment. Under such circumstances, the IBC member shall not be present during IBC deliberations, except to provide information requested by the IBC. Each member of the IBC shall respect and preserve the confidentiality of information he/she receives as a member of the IBC, and shall use, discuss, and/or disclose such information only for purposes related to deliberations or other assigned business of the IBC.

- *Dr. Otero reported a Conflict of Interest with Dr. Ivashkiv. Dr. Otero will abstain from voting on this registration.*

Protocols on Agenda

The Institutional Biosafety Committee (IBC) and Biosafety staff perform pre-reviews on all protocol submissions, including consideration of: agent characteristics (e.g., virulence, pathogenicity, environmental stability, replication competence), the types of manipulations planned, the sources of nucleic acid sequences (species), the nature of the nucleic acid sequences (e.g., structural, enzyme, oncogene, toxin, gene regulator), the hosts and vectors to be used, whether an attempt will be made to obtain expression of a transgene, and if so, the function of the protein in the proposed system.

IBC review includes: (i) independent assessment and setting of the containment levels required by the NIH Guidelines for the proposed research; (ii) assessment of the facilities, procedures, practices, and training and expertise of personnel involved in recombinant or synthetic nucleic acid molecule research; (iii) for recombinant or synthetic nucleic acid molecule research involving human research participants assessment focused on biosafety issues (e.g., administration, shedding) (iv) set containment levels in concert with the WCM IACUC.

Prior to reviewing a registration at the IBC meeting, the Principal Investigators laboratory is inspected to confirm that facilities and biocontainment equipment (e.g., certified Class II biological safety cabinets) are available and appropriate. We also determine if all laboratory personnel are appropriately trained to adhere to institutional and federal regulations to ensure the safe and compliant conduct of research.

All protocol submissions are made available to IBC members before the meeting. During the meeting, reviewers' and members' questions are presented, discussed, and sufficiently addressed. Protocols are voted on and acted upon by the IBC, i.e., applications are either approved, rejected or returned to the applicant to request clarifying information. Protocols deemed to require changes are returned to the PI for revision before subsequent review by the IBC. Principal Investigators are then provided the results of the IBC review and official approval.

Following initial approval, IBC registration remains valid for a period of two years. During this two-year period, laboratory inspections and review of training records of lab staff are conducted annually in accordance with Weill Cornell policies.

Human Subjects Research/Human Gene Transfer: Initial

HS Record Number: 26-06030415

HS PI Name: Ma, Barbara

Record Title:

IOV-GE1-201: A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors

RS Record Number: 26-0049

Notes: The assigned IBC member reviewed the protocol. The reviewer noted the IBC application does not provide the actual route, dose, and number of days of infusion. This information has been requested to be added and with these administrative changes, the reviewer recommends approval at BSL-2 with standard contact precautions.

Decision: Approved with administrative changes

Laboratory Safety Registrations- Amendments

Record Number: 20-0009

PI Name: Samie R Jaffrey

Submission Type: Amendment

Notes: The assigned IBC member reviewed the lab protocol. This amendment updates the research description to include work with a new agent, AAV. No issues were raised. The reviewer recommends approval at previously approved biosafety levels and AAV to be approved in vitro at BSL-2 and in vivo at ABSL-1.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, up regulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)
Adeno-Associated Virus (AAV)		AAV2, AAV PHP.eB, AAV9, AAV P HP.eB-Cyclone-Cre, AAV2/6-ACC ENT (addgene)	Replication Incompetent/Deficient	HEK293T	Both	In vivo model ~ Human	HECT domain of NED D41 ligase, calcium, sodium and potassium channel regulators, Cre-recombinase	Human	Gene Expression Regulators	Direct inject into in vivo model ~ Express/Upregulate gene of interest ~ Repress/Downregulate gene of interest ~ Transfect cell line ~ Transfect cells	ABSL-1 ~ BSL-2

Laboratory Safety Registrations- Renewals

Record Number: 19-0152

PI Name: Christopher E Mason

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. The reviewer requested to remove in vivo lentiviral work and suggested clarification if inactivated samples are still being received. Additionally, the risk/exposure language was requested to be updated. No other issues were raised. With these administrative changes, the reviewer recommends approval of Lentivirus and SARS-CoV at BSL-2+.

Decision: Approved with administrative changes

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviridae/Lentiviridae]		lentiCRISPR v2, pPlatTET, Lenti-dCas9-KRAB, pLX_311, pHR-SFFV, pHRdSV4 0, pLVX	Replication Incompetent/Deficient ~ Self-Inactivating	HEK293T, HEK293FT	In Vitro	Human	Cas9, dCas9-fusion proteins, Dsup, sgRNAs for CRISPR editing	Human	Antibiotic Resistance ~ Gene Expression Regulators	Express/Upregulate gene of interest ~ Repress/Downregulate gene of interest ~ Transfect cell line ~ Transfect cells	BSL-2+	NIH Applicable	Section II I-D-1 ~ Section III-D-3

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
*Other	SARS CoV-2	Inactivated Patient samples (Bermuda) nasopharyngeal swab	Replication Incompetent/Deficient	In Vitro	Other/NP swabs in inactivation buffer are aliquoted and sent to NYC Genome center for sequencing	BSL-2+	Not rDNA	

Record Number: 19-0447

PI Name: Francis S Lee

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. The reviewer noted that Canine Adenovirus is not currently described in this PI's IACUC protocol. No other issues were raised. The reviewer recommends approval at previously approved biosafety levels and increasing AAV to be approved at ABSL-1, BSL-2.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Canine Adenovirus [CAV-1, CAV-2]		CAV-CR E, CAV-G FP (serotype 20)	Replication Incompetent/ Deficient	HEK293	Both	In vivo model	siRNA construct targeting mammalian genes	Other/Canine	Gene Expression Regulators ~ Marker/Reporter ~ Other/Neurotransmitter ~ Transporter ~ Unknown	Create virions ~ Express/Upregulate gene of interest ~ Repress/ Downregulate gene of interest ~ Transfect cell line	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-4
Adeno-Associated Virus (AAV)		pAAV-H1, HM4DI, GFP (serotype 8)	Replication Incompetent/ Deficient	HEK293	Both	In vivo model	siRNA construct targeting mammalian genes (HM4DI)	Human ~ Murine	Gene Expression Regulators ~ Marker/Reporter ~ Other/Neurotransmitter ~ Transporter ~ Unknown	Create virions ~ Express/Upregulate gene of interest ~ Repress/ Downregulate gene of interest ~ Transfect cell line	ABSL-1 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-4

Record Number: 19-0732

PI Name: Lonny R. Levin

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols. The reviewer requested to update the IBC application to reflect the work described in the description. Additionally, the lentiviral work needs to indicate both in vitro and in vivo, and the related in vivo work should be included. No other issues were raised. With these administrative changes, the reviewer recommends approval at previously approved biosafety levels.

Decision: Approved with administrative changes

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Baculovirus [Viral vector/Insect virus]		baculovirus expression vectors	Replication Incompetent/ Deficient	SF9, Hi5	In Vitro	Insect	ADCY10, soluble adenylyl cyclase	Human ~ Murine ~ Parasite	Unknown	Create virions ~ Express/Upregulate gene of interest	BSL-1	NIH Applicable	Section II I-D-2 ~ Section III-D-3
Lentivirus [Retroviral/Lentiviral]		pLent-6, pCW57	Replication Incompetent/ Deficient	293, and other mammalian cell lines.	Both	In vivo model ~ Human	Soluble Adenylyl cyclase (ADCY10); GFP and luciferase	Human ~ Murine	Marker/Reporter ~ Other/Enzyme making CAMP	Create virions ~ Express/Upregulate gene of interest ~ Transfect cell line ~ Transfect cells ~ Transfect cells / introduce into in vivo model	BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3

Record Number: 19-0735

PI Name: James C. Lo

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted minor administrative changes and genes added to this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adenoviruses [Human, all types]		pAd/CMV/V5-DEST	Replication Incompetent/Deficient	293T, F442A, HEK293, L1, phoenix, min6, ins1	Both	In vivo model~ Human	adipsin/complement factor D, fam20c, C3aR1, C5aR1, C3, fam20 family, complement family, etv1, cd81	Human ~ Murine ~ Other/ Human, Murine, Rat	Gene ~ Expression Regulators	Create virions ~ Direct inject into in vivo model ~ Express/Uregulate gene of interest ~ Transfect cell line	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3 ~ Section III-D-4
Lentivirus [Retroviridae/Lentiviridae]		pLKO, pCDH,	Replication Incompetent/Deficient	293T, F442A, HEK293, L1, phoenix, min6, ins1	In Vitro	In vivo model~ Human	adipsin/complement factor D, fam20c, C3aR1, C5aR1, C3, fam20 family, complement family, adipsin/complement factor D, fam 20c, C3a R1, C5aR1, C3, fam20 family, complement family, Dusp2 6, Tbx5, Atf6, Turbo-ID, GFP, Rab27a, Scn5a, cd38, nampt, spread2, beta catenin, cnpy4, cd36	Human ~ Murine ~ Other/ Human, Murine, Rat	Gene ~ Expression Regulators	Create virions ~ Express/Uregulate gene of interest ~ Transfect cell line	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3
Retrovirus [Amphotropic]		pMKO, pMSCV	Replication Incompetent/Deficient	293T, F442A, HEK293, L1, phoenix, min6, ins1	In Vitro	In vivo model~ Human	adipsin/complement factor D, fam20c, C3aR1, C5aR1, C3, fam20 family, complement family, Dusp26, Tbx5, Atf6, Turbo-ID, GFP, Rab27a, Scn5a, cd38, nampt, spread2, beta catenin, cnpy4, cd36	Human ~ Murine ~ Other/ Human, Murine, Rat	Gene ~ Expression Regulators	Create virions ~ Express/Uregulate gene of interest ~ Transfect cell line	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3
Adeno-Associated Virus (AAV)		cis-plasmid, trans-plasmid, pDF6, AAV1-9	Replication Incompetent/Deficient	293T, F442A, HEK293, L1, phoenix, min6, ins1	Both	In vivo model~ Human	adipsin/complement factor D, fam20c, C3aR1, C5aR1, C3, fam20 family, complement family, Dusp26, Tbx5, Atf6, Turbo-ID, GFP, Rab27a, Scn5a, cd38, nampt, spread2, beta catenin, cnpy4, cd36, adiponectin	Human ~ Murine ~ Other/ Human, Murine, Rat	Gene ~ Expression Regulators	Create virions ~ Direct inject into in vivo model ~ Express/Uregulate gene of interest ~ Transfect cell line	ABSL-1 ~ BSL-1	NIH Applicable	Section II I-D-4

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
*Other	inactivated COVID-19 in vivo modelspecimens (blood components-sera, plasma, tissue: fat, pancreas)	SARS-CoV-2	Replication Competent	In Vitro	Isolation DNA/RNA	BSL-2	Not rDNA	
*Other	COVID-19 patient specimens (blood components-sera, plasma, tissue: fat, pancreas)	SARS-CoV-2	Replication Competent	In Vitro	Isolation DNA/RNA ~ Other/inactivation of sample, isolate proteins, immunoassays, pathologic/microscopic examination	BSL-2+	Not rDNA	

Record Number: 19-0750

PI Name: Laura Alonso

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adenovirus [Human, all types]		Ad-5 (DE1/E3)	Attenuated ~ Replication Incompetent/Deficient	N/A vectors purchased from Vector Biolabs	In Vitro	In vivo model ~ Human	CCND2, shCCND2, shIRS2, CDKN2A, shIR, Cre, ATF 6a, LacZ, Insulin2, Atf6b, Foxo1, E2f1, MAPK10, CRE B3L2, G6PC2, MAPK8, SE MA3C, Creb3, FoxO1ADA, C/EBP-zeta, Parp11, iCre	Bacteria ~ Human ~ Murine ~ Virus	Gene Expression Regulators ~ Hormone ~ Other/ Recombinant gene will either downregulate or upregulate specific genes when added to cell culture	Express/ Upregulate gene of interest ~ Repress/Downregulate gene of interest	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1

Record Number: 21-0081

PI Name: Baran Ersoy

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adenovirus [Human, all types]		Cre-GFP and control GFP (Gene Transfer Vector Core at the University of Iowa), Ad5 (E1, E3 deleted), Ad-CMV-Flp (Flp Recombinase), Ad-CMV-iCre (Cre Recombinase), Ad-Anp3 2b, Zfb395, S100a8 and S100a9, Cps1, ACSS1, ACSS3 and LacZ control	Replication Incompetent/Deficient	293mouse hepatocytes, HEK 293A	Both	In vivo model ~ Human	Cre-GFP, GFP cre recombinase, flp recombinase Ad-Anp32b, Zfb395, S100a8 and S100a9: U6 promoter and a synthetic gRNA targeting Anp32b, Zfp 395, S100a8 and S100a9 will be inserted into the adenoviral shuttle plasmid. Carbamoyl-phosphate synthase 1 (Cps1) cDNA	Bacteriophage ~ Human ~ Jellyfish ~ Murine	Gene Expression Regulators ~ Hormone ~ Marker/ Reporter ~ Unknown	Create virions ~ Direct inject into in vivo model ~ Express/Upregulate gene of interest ~ Transfect cell line ~ Transfect cells	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3 ~ Section III-D-4

Adeno-Associated Virus (AAV)		AAV8, AAV LacZ	Replication Incompetent/ Deficient	N/A	In Vivo	In vivo model	flp and cre recombinase, LacZ	Bacteria ~ Bacteriophage	Other/ Target gene deletion	Create virions ~ Direct inject into in vivo model ~ Express/Upreregulate gene of interest	ABSL-1 ~ BSL-1	NIH Applicable	Section II I-D-4
Lentivirus [Retroviridae/Lentiviridae]		pLKO	Replication Incompetent/ Deficient	293E, Hepa1.6, HepG2, Min 6	In Vitro	In vivo model ~ Human	Acot9, Ybx1, Cps1, Anp32b, Zfp395, S100a8, S100a9 in PcDNA3.1 plasmid	Human ~ Murine	Gene Expression Regulators ~ Hormone	Create virions ~ Express/Upreregulate gene of interest ~ Transfect cell line	BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
*Other	Akkermansia	Muciniphilia	Replication Competent	In Vivo	Introduction into in vivo model	ABSL-1 ~ BSL-1	Not rDNA	

Record Number: 21-0103

PI Name: Shannon Reilly

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviridae/Lentiviridae]		pLVX-Puro (HIV-1)	Attenuated ~ Replication Incompetent/Deficient	293T	In Vitro	In vivo model	STAT3 GPAT3	Human ~ Murine	Gene Expression Regulators ~ Oncogenic Gene Sequences	Create virions ~ Express/Upreregulate gene of interest ~ Repress/Downregulate gene of interest ~ Transfect cell line ~ Transfect cells	BSL-2+	NIH Applicable	Section II I-D-1 ~ Section III-D-3

Record Number: 23-0099

PI Name: Rohit Sharma

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
------------------------------------	--------------------------	---------------------------------------	----------------------------------	---	----------------------	---------------------------	--	---------------------------------------	--	--------------------------------------	-----------------------------	----------------------	---------------------------

Adenovirus [Human, all types]		Ad-MEF2A (Human Adenovirus Type5 (dE1/E3))(V ector Biolabs)	Replicatio n Incompet ent/Deficie nt	N/A	In Vitro	In vivo model~ Human	The myocyte enhancing factor-2 (MEF-2) family of transcription factors includes four splice variants A, B, C and D which encode muscle- specific DNA binding proteins that recognize an A/T rich sequence [CTA (A/T)4 TAG] localized in the control regions of numerous muscle-specific genes.	Human	Gene Expression Regulators	Express/Upre gulate gene of interest~ Transfect cell line~ Transfect cells	BSL-2	NIH Applicable	Section III- D-1
-------------------------------------	--	---	--	-----	----------	----------------------------	---	-------	----------------------------------	--	-------	-------------------	---------------------

Record Number: 25-0023

PI Name: Jinsook Son

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adenovirus [Human, all types]		DE1/E3- deleted Ad5 vector (serotype 5)	Replication Incompetent/ Deficient	NA- purchased	In Vitro	In vivo model~ Human	BACH2, FOXO1, HMGM2	Human ~ Murine	Gene Expression Regulators	Express/ Upregulate gene of interest ~ Repress/Downr egulate gene of interest ~ Transfect cell line	BSL-2	NIH Applicable	Section II I-D-1
Lentivirus [Retroviridae/Lentiviridae]		pMDLg/p RRE and pRSV-Rev.	Replication Incompetent/ Deficient ~ Self- Inactivating	NA- purchased	In Vitro	In vivo model~ Human	BACH2, HMGM2	Human ~ Murine	Gene Expression Regulators	Express/ Upregulate gene of interest ~ Repress/Downr egulate gene of interest ~ Transfect cell line	BSL-2	NIH Applicable	Section II I-D-1 ~ Section III- D-3

Record Number: 25-0039

PI Name: Norihiro Goto

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. The reviewer requested to check the box for oncogene due to the gene of interest Rspo3, and to increase the biosafety level. No other issues were raised. With these administrative changes, the reviewer recommends approval at previously approved biosafety levels.

Decision: Approved with administrative changes

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviridae/Lentiviridae]		knockout-LentiCRISPR v2 (Addgene, #52961), knockdown-LT3GEPiR plasmid (Addgene, #111177), lentiviral backbone constructs - pSpax2 (Addgene, #12260) and pMD2.G (Addgene, #12259)	Replication Incompetent/Deficient	HEK293	Both	In vivo model~ Human	Rspo3, Gata6, Sox 17, and Ahcy	Human	Gene Expression Regulators ~ Oncogenic Gene Sequences ~ Other/ Modulation of the targeted genes will affect the cell growth of the cancer organoids and fibroblast.	Express/ Upregulate gene of interest ~ Transfect cell line ~ Transfect cells ~ Transfect cells / introduce into in vivo model	ABSL-2 ~ BSL-2+	NIH Applicable	Section II I-D-1 ~ Section III-D-3

Acknowledgement of Laboratory Safety Registrations: No IBC-Applicable Work Conducted

Record Number	PI Name	Laboratory Safety Registration Submission Type
19-0431	Surya V Seshan	Lab Registration - Renewal
23-0097	Maria T Salpietro	Lab Registration - Renewal

Laboratory Safety Registrations: Exempt

Record Number	PI Name	Laboratory Safety Registration Submission Type
25-0021	Myles Wolf	Lab Registration - Renewal

Acknowledgment of Approved Administrative Amendments

Record Number	PI Name	Laboratory Safety Registration Submission Type
19-0115	Lionel B Ivashkiv	Lab Registration - Amendment

The meeting adjourned at 10:19 AM.

